|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,398,000 |
Market
Cap: |
389.26(M) |
Last
Volume: |
1,040,465 |
Avg
Vol: |
716,466 |
52
Week Range: |
$3.38 - $6.66 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 803 |
Guru Rank Value : 1 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
121,098 |
133,534 |
375,216 |
Total Sell Value |
$0 |
$513,345 |
$588,387 |
$2,607,605 |
Total People Sold |
0 |
5 |
6 |
6 |
Total Sell Transactions |
0 |
10 |
13 |
31 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Watkins Thomas |
Director |
|
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
25,000 |
|
- |
|
Milano Vincent |
Director |
|
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
|
- |
|
Dugan Richard W |
Director |
|
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
30,770 |
|
- |
|
Watkins Thomas |
Director |
|
2018-05-03 |
4 |
OE |
$4.98 |
$74,700 |
D/D |
15,000 |
20,000 |
|
- |
|
Dugan Richard W |
Director |
|
2018-03-19 |
4 |
OE |
$4.98 |
$74,700 |
D/D |
15,000 |
25,770 |
|
- |
|
Gulino Richard L. |
SVP, General Counsel & Sec. |
|
2018-03-01 |
4 |
S |
$18.71 |
$68,473 |
D/D |
(3,660) |
115,073 |
|
- |
|
Birznieks Gunther |
SVP, Business Development |
|
2018-03-01 |
4 |
S |
$18.72 |
$159,605 |
D/D |
(8,525) |
139,841 |
|
- |
|
Kelly James Patrick |
EVP & Chief Financial Officer |
|
2018-03-01 |
4 |
S |
$18.72 |
$159,712 |
D/D |
(8,532) |
199,534 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2018-03-01 |
4 |
S |
$18.72 |
$1,141,003 |
D/D |
(60,966) |
1,182,872 |
|
- |
|
Gulino Richard L. |
SVP, General Counsel & Sec. |
|
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
118,733 |
|
- |
|
Birznieks Gunther |
SVP, Business Development |
|
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
148,366 |
|
- |
|
Kelly James Patrick |
EVP & Chief Financial Officer |
|
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
208,066 |
|
- |
|
Reverberi Gian Piero |
SVP & Chief Commercial Officer |
|
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
140,000 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
1,243,838 |
|
- |
|
Kelly James Patrick |
EVP & Chief Financial Officer |
|
2018-01-02 |
4 |
S |
$15.35 |
$140,494 |
D/D |
(9,155) |
168,066 |
|
- |
|
Kelly James Patrick |
EVP & Chief Financial Officer |
|
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
177,221 |
|
- |
|
Gulino Richard L. |
SVP, General Counsel & Sec. |
|
2018-01-02 |
4 |
S |
$15.20 |
$157,565 |
D/D |
(10,367) |
88,733 |
|
- |
|
Gulino Richard L. |
SVP, General Counsel & Sec. |
|
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
99,100 |
|
- |
|
Reverberi Gian Piero |
SVP & Chief Commercial Officer |
|
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
110,000 |
|
- |
|
Birznieks Gunther |
SVP, Business Development |
|
2018-01-02 |
4 |
S |
$15.26 |
$130,777 |
D/D |
(8,568) |
118,366 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2018-01-02 |
4 |
S |
$15.30 |
$2,933,127 |
D/D |
(191,760) |
1,183,838 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2018-01-02 |
4 |
OE |
$0.00 |
$1,440,000 |
D/D |
293,750 |
1,205,373 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2017-12-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
1,031,848 |
|
- |
|
Bate Kenneth |
Director |
|
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
Bate Kenneth |
Director |
|
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
277 Records found
|
|
Page 9 of 12 |
|
|